本帖最后由 maicon08 于 2023-4-28 15:12 编辑
$ p- H: W& }+ E7 b0 j; m0 v+ j: n3 k* J; |/ R8 W% \5 {' D# s+ t5 k
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。! I0 V# c0 i, h: m
. U+ \5 u# E: X$ N1 A! R' b5 ~/ Qhttps://www.163.com/dy/article/I3BTTPRD053438SI.html
6 D& @- a' }3 t( r. z }5 y( {8 ^
2 N) }2 w. w; |, u: v8 A9 p
在研疗法-免疫治疗
& D$ i" _7 A* g3 i- }4 k: i6 M+ `Developmental Therapeutics—Immunotherapy1 ^0 m; H: N( i7 q$ Y9 e
k7 p9 u$ X' _! N+ c W1 x摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 . S3 p# p' q1 o' d
在研疗法-分子靶向药物和肿瘤生物学( r) \7 j- b; c
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology & X8 d, w! n/ Q- E y& v1 j: K1 d
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
' I. c. ~8 V* S( J; q( {! |
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 8 s) x: y7 S) |0 m4 g- {% r
胃肠道肿瘤-结直肠癌和肛门癌
$ o0 l( G! h5 F/ L0 W0 h Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 & [: y; S1 i: E, v8 {6 F
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ( j% R1 ~4 a& J
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
) s% L- _. }" I
妇科肿瘤 Gynecologic Cancer
& S- K* J. A8 _% P& q. y摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
& `4 S$ z" W* r4 \% y
头颈肿瘤 ]) v0 d6 k' b( M4 |
Head and Neck Cancer " i: ~: q; h* g, y: E( a0 F
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 ( a2 r A7 B, e; J7 G7 q# }
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 & r3 h1 U L/ y
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 ; y& D$ N. |$ N& o
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
: F5 c2 U: A p% _% z1 r7 X摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 . h6 c0 i( t. F/ O* g. s) p
血液系统恶性肿瘤-浆细胞疾病" p) I8 b6 E- d' V
Hematologic Malignancies—Plasma Cell Dyscrasia 6 H7 {: Y/ ?: U4 M4 e) ~
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 8 y# R- J9 L2 b9 W+ I
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
! q. H0 s; ?1 U, E: T Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 5 O8 `/ `9 I8 g( Z
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 % G- i0 ~/ R1 J/ E' ]2 a
肺癌-转移性非小细胞肺癌
- z3 ~$ [% f. `* x8 ~- {, E( f Lung Cancer—Non-Small Cell Metastatic
6 H5 ~0 n; S9 I2 B摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
8 \' ]3 }8 D4 a/ l
' N/ x+ r9 z5 B5 G摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 1 f: e* T; o: e$ f
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
# S, P0 k3 L9 m+ r, c% ~
黑色素瘤/皮肤癌
; z4 x+ U% G- u3 B G+ \ Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
' k# g m! h* ^3 }4 ^$ J
快速摘要报告 }1 e% f* k$ h( x
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心 - l0 Z, R# K9 h* M. k3 \+ l# V
临床科学研讨会
1 p$ p8 U2 _! C, E& z. F Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
0 h$ N' O7 A, u, J8 x2 T
$ p/ u6 ]2 ]: R& `) x* E | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
